Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Karsten Eichholz, … , Afam A. Okoye, Lawrence Corey
Karsten Eichholz, … , Afam A. Okoye, Lawrence Corey
Published April 1, 2024
Citation Information: J Clin Invest. 2024;134(7):e169309. https://doi.org/10.1172/JCI169309.
View: Text | PDF
Research Article AIDS/HIV Article has an altmetric score of 10

Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers

  • Text
  • PDF
Abstract

Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4+ T cells. We engineered an anti–PD-1 chimeric antigen receptor (CAR) to assess the impact of PD-1 depletion on viral reservoirs and rebound dynamics in SIVmac239–infected rhesus macaques (RMs). Adoptive transfer of anti–PD-1 CAR T cells was done in 2 SIV-naive and 4 SIV-infected RMs on antiretroviral therapy (ART). In 3 of 6 RMs, anti–PD-1 CAR T cells expanded and persisted for up to 100 days concomitant with the depletion of PD-1+ memory T cells in blood and tissues, including lymph node CD4+ follicular helper T (TFH) cells. Loss of TFH cells was associated with depletion of detectable SIV RNA from the germinal center (GC). However, following CAR T infusion and ART interruption, there was a marked increase in SIV replication in extrafollicular portions of lymph nodes, a 2-log higher plasma viremia relative to controls, and accelerated disease progression associated with the depletion of CD8+ memory T cells. These data indicate anti–PD-1 CAR T cells depleted PD-1+ T cells, including GC TFH cells, and eradicated SIV from this immunological sanctuary.

Authors

Karsten Eichholz, Yoshinori Fukazawa, Christopher W. Peterson, Francoise Haeseleer, Manuel Medina, Shelby Hoffmeister, Derick M. Duell, Benjamin D. Varco-Merth, Sandra Dross, Haesun Park, Caralyn S. Labriola, Michael K. Axthelm, Robert D. Murnane, Jeremy V. Smedley, Lei Jin, Jiaxin Gong, Blake J. Rust, Deborah H. Fuller, Hans-Peter Kiem, Louis J. Picker, Afam A. Okoye, Lawrence Corey

×

Figure 4

Anti–PD-1 CAR T cells deplete PD-1+ T cells in SIV-infected RMs on ART.

Options: View larger image (or click on image) Download as PowerPoint
Anti–PD-1 CAR T cells deplete PD-1+ T cells in SIV-infected RMs on ART.
...
Schematic of the in vivo animal study (n = 4). Dates for tissue surgery, lymphodepletion, duration of ART, and tocilizumab treatment are noted (A). Absolute count of EGFRt-expressing CD3+ T cells in peripheral blood for the duration of the study (B). Longitudinal EGFRt-expressing CD3+ T cells in peri.LN. (C). Flow cytometric analysis of PD-1 and CXCR5 expression on CD4+ and CD8+ total memory T cells in Peri.LN from RM3 (D). Frequency of TFH cells in CD4+ total memory T cells (E). Combined immunofluorescence and RNA FISH staining on LN tissue section for CD20 (gray), CD3 (green), PD-1 (red), CD8α RNA (blue), and CAR RNA (magenta) (F). Magenta arrows point to intrafollicular CD8+ CAR T cells, and red arrows point to residual TFH cells after infusion. TFH cells are characterized by CD3 and PD-1 dual staining within the B cell follicle and appear yellow (F). Original magnification, ×40. Absolute count of PD-1+ CD4+ and CD8+ memory T cells in peripheral blood (G). PD-1 expression on Peri.LN CD4+ memory T cells and CD8+ memory T cells (H).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 17 X users
20 readers on Mendeley
See more details